A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 Study

被引：5

作者：

Brivio, Erica ^{[1
]}

Lopez-Yurda, Marta ^{[1
,2
,3
]}

Ownes, Cormac ^{[4
]}

Diaz de Heredia, Cristina ^{[5
]}

Bielorai, Bella ^{[6
]}

Rossig, Claudia ^{[7
]}

Van der Velden, Vincent ^{[8
]}

Ammerlaan, Anneke C. J. ^{[1
]}

van der Sluis, Inge M. ^{[1
]}

Den Boer, Monique L. ^{[1
,2
]}

Chen, Ying ^{[9
]}

Sleight, Barbara ^{[10
]}

Brethon, Benoit ^{[11
]}

Nysom, Karsten ^{[12
]}

Stary, Jan ^{[13
]}

Ora, Ingrid ^{[14
]}

Chen-Santel, Christiane ^{[15
]}

Vinti, Luciana ^{[16
]}

Locatelli, Franco ^{[17
]}

Zwaan, Christian Michel ^{[1
,2
]}

机构：

[1] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands

[2] Erasmus MC, Dept Pediat Oncol Hematol, Sophia Childrens Hosp, Rotterdam, Netherlands

[3] Netherlands Canc Inst, Dept Biometr, Amsterdam, Netherlands

[4] Our Ladys Childrens Hosp Crumlin, Dublin, Ireland

[5] Hosp Univ Vall dHebron Vall dHebron, Pediat Oncol & Hematol Dept, Barcelona, Spain

[6] Sheba Med Ctr, Div Pediat Hematol & Oncol, Ramat Gan, Israel

[7] Univ Childrens Hosp Muenster, Pediat Hematol & Oncol, Munster, Germany

[8] Erasmus MC, Dept Immunol, Rotterdam, Netherlands

[9] Pfizer Inc, Clin Pharmacol, San Diego, CA USA

[10] Pfizer Inc, Groton, CT 06340 USA

[11] Univ Paris, Robert Debre Hosp, AP HP, Dept Pediat Hematol & Immunol, Paris, France

[12] Rigshosp, Copenhagen, Denmark

[13] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic

[14] Karolinska Univ Hosp, Pediat Oncol Unit, Stockholm, Sweden

[15] Charite Univ Med Berlin, Div Hematol & Oncol, Dept Pediat, Berlin, Germany

[16] IRCCS Bambino Gesu Childrens Hosp, Dept Pediat Hematol Oncol Cell & Gene Therapy, Rome, Italy

[17] Univ Rome Sapienza, Dept Hematol Oncol & transfus Med, Osped Pediat Bambino Gesu, Rome, Italy

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-122411

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2629

引用

页数：5

共 50 条

[1] A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study
Brivio, Erica
Locatelli, Franco
Thano, Adriana
Petit, Arnaud
Vormoor, Britta Julia
Rives, Susana
Bielorai, Bella
Rossig, Claudia
Rizzari, Carmelo
Van der Velden, Vincent H. J.
Ammerlaan, Anneke C. J.
Den Boer, Monique L.
Sleight, Barbara
Engstler, Gernot
Stary, Jan
Sirvent, Francisco Jose Bautista
Chen-Santel, Christiane
Bruno, Benedicte
Bertrand, Yves
Rialland, Fanny
Plat, Genevieve
Reinhardt, Dirk
Vinti, Luciana
von Stackelberg, Arend
Zwaan, Christian Michel
BLOOD, 2020, 136
[2] A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)
Brivio, Erica
Locatelli, Franco
Lopez-Yurda, Marta
Malone, Andrea
Diaz-de-Heredia, Cristina
Bielorai, Bella
Rossig, Claudia
van der Velden, Vincent H. J.
Ammerlaan, Anneke C. J.
Thano, Adriana
van der Sluis, Inge M.
den Boer, Monique L.
Chen, Ying
Sleight, Barbara
Brethon, Benoit
Nysom, Karsten
Sramkova, Lucie
Ora, Ingrid
Vinti, Luciana
Chen-Santel, Christiane
Zwaan, Christian Michel
BLOOD, 2021, 137 (12) : 1582 - 1590
[3] Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059
Wu, Jen-Hao
Pennesi, Edoardo
Bautista, Francisco
Garrett, May
Fukuhara, Kei
Brivio, Erica
Ammerlaan, Anneke C. J.
Locatelli, Franco
van der Sluis, Inge M.
Rossig, Claudia
Chen-Santel, Christiane
Bielorai, Bella
Petit, Arnaud
Stary, Jan
Diaz-de-Heredia, Cristina
Rives, Susana
O'Marcaigh, Aengus
Rizzari, Carmelo
Engstler, Gernot
Nysom, Karsten
Rubio-San-Simon, Alba
Bruno, Benedicte
Bertrand, Yves
Brethon, Benoit
Rialland, Fanny
Plat, Genevieve
Dirksen, Uta
Sramkova, Lucie
Zwaan, C. Michel
Huitema, Alwin D. R.
CLINICAL PHARMACOKINETICS, 2024, 63 (07) : 981 - 997
[4] Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II Trial
Pennesi, Edoardo
Brivio, Erica
Pelletier, Kathleen B.
Chen, Ying
Huitema, Alwin D. R.
Jiang, Yilin
Ammerlaan, Anneke C. J.
Sleight, Barbara
Locatelli, Franco
Van der Sluis, Inge M.
Rossig, Claudia
Chen-Santel, Christiane
Bielorai, Bella
Petit, Arnaud
Stary, Jan
Sramkova, Lucie
de Heredia Rubio, Cristina Diaz
Rives, Susana
O'Marcaigh, Aengus
Rizzari, Carmelo
Engstler, Gernot
Nysom, Karsten
Rubio-San-Simon, Alba
Sirvent, Francisco J. Bautista
Bruno, Benedicte
Bertrand, Yives
Brethon, Benoit
Rialland, Fanny
Plat, Genevieve
Dirksen, Uta
Garrett, May
Zwaan, Christian M.
BLOOD, 2022, 140 : 8845 - 8847
[5] Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study
DeAngelo, Daniel J.
Stock, Wendy
Stein, Anthony S.
Shustov, Andrei
Liedtke, Michaela
Schiffer, Charles A.
Vandendries, Erik
Liau, Katherine
Ananthakrishnan, Revathi
Boni, Joseph
Laird, A. Douglas
Fostvedt, Luke
Kantarjian, Hagop M.
Advani, Anjali S.
BLOOD ADVANCES, 2017, 1 (15) : 1167 - 1180
[6] A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1)
Nakayama, Hideki
Ogawa, Chitose
Sekimizu, Masahiro
Fujisaki, Hiroyuki
Kosaka, Yoshiyuki
Hashimoto, Hiroya
Saito, Akiko M.
Horibe, Keizo
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 116 (04) : 612 - 621
[7] A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1)
Hideki Nakayama
Chitose Ogawa
Masahiro Sekimizu
Hiroyuki Fujisaki
Yoshiyuki Kosaka
Hiroya Hashimoto
Akiko M. Saito
Keizo Horibe
International Journal of Hematology, 2022, 116 : 612 - 621
[8] Correction to: A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1)
Hideki Nakayama
Chitose Ogawa
Masahiro Sekimizu
Hiroyuki Fujisaki
Yoshiyuki Kosaka
Hiroya Hashimoto
Akiko M. Saito
Keizo Horibe
International Journal of Hematology, 2023, 117 : 786 - 786
[9] Weekly Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia.
DeAngelo, Daniel
Stock, Wendy
Petersdorf, Stephen
Wang, Shaw-Ling
Volkert, Angela
Vandendries, Erik
Advani, Anjali
BLOOD, 2012, 120 (21)
[10] Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial
Pennesi, Edoardo
Brivio, Erica
Ammerlaan, Anneke C. J.
Jiang, Yilin
van der Velden, Vincent H. J.
Beverloo, H. Berna
Sleight, Barbara
Locatelli, Franco
Brethon, Benoit
Rossig, Claudia
Engstler, Gernot
Nilsson, Anna
Bruno, Benedicte
Petit, Arnaud
Bielorai, Bella
Rizzari, Carmelo
Rialland, Fanny
Rubio-San-Simon, Alba
Bautista Sirvent, Francisco J.
Diaz-de-Heredia, Cristina
Rives, Susana
Zwaan, Christian M.
HAEMATOLOGICA, 2024, 109 (10) : 3157 - 3166

← 1 2 3 4 5 →